Particle.news
Drug Development Drug Pricing Weight Loss Drugs Clinical Trials Drug Approval Prescription Drugs Diabetes Treatment Vaccines Drug Manufacturing Vaccine Development Cancer Treatment Prescription Medications Diabetes Medications Drug Sales Weight-loss Drugs Drug Safety Drug Regulation Drug Shortages Drug Approval Process Biotechnology Obesity Treatment Weight-Loss Drugs Weight Loss Medications Obesity Treatments Abortion Medications Abortion Medication Diabetes Treatments Supply Chain Pharmacy Benefit Managers Drug Production Retail Pharmacy Diabetes Weight Loss Biopharmaceuticals Rare Diseases Manufacturing Diabetes Drugs Generic Drugs Alzheimer's Disease Pain Management Drug Supply Chain Novo Nordisk Weight Loss Treatments Pharmaceutical Companies Regulations Obesity Opioid Crisis Drug Efficacy Gene Therapy Research and Development Drug Side Effects Competition Regulatory Compliance Drug Costs Medicines Antidepressants Pfizer Over-the-Counter Medications Companies Insulin FDA Regulations Acquisitions Cancer Treatments Alzheimer's Drugs COVID-19 Vaccines Alzheimer's Treatment COVID-19 Treatments Medication Safety Therapeutics Immunology Moderna Drug Companies Drug Discovery Drug Accessibility Hormonal Treatments Generics Drug Coverage Corporate Governance Clinical Studies Specialty Pharmaceuticals Medication Drug Comparison Drugmaker Regulatory Affairs Inhalers Cardiovascular Drugs Antibiotics Drug Candidates Abortion Pill Drug Mechanism Abortion Drug Access Recalls Cancer Drugs FDA Approval GLP-1 Drugs Contraceptives Opioids Eli Lilly Drug Marketing
The pharmaceutical giant posted a 45% revenue increase driven by diabetes and weight-loss drugs but lowered earnings guidance due to a $1.57 billion charge tied to a cancer drug acquisition.
